evipedia.ai
← Back

Nobiletin for Health & Longevity

Evidence Review created on 09/23/2026 using AI4L / Opus 5.5

Also known as: Hexamethoxyflavone, NOB

Motivation

Nobiletin is a natural plant compound concentrated in the peel of citrus fruits such as mandarins, bitter orange, and the Okinawan shiikuwasa. It has drawn attention in longevity circles because it appears to strengthen the body’s internal daily clock, the system that times sleep, energy use, and repair. In laboratory animals it has protected against metabolic decline and memory loss.

Dried citrus peel has been used in traditional East Asian medicine for centuries, and purified nobiletin is now sold as a dietary supplement, often combined with melatonin or with related citrus compounds. Human research is still small: a handful of trials in older adults have tested nobiletin-containing products, mainly for memory and metabolic health, usually alongside other ingredients.

This review examines what is known about nobiletin as a health and longevity supplement: the quality of the human and animal evidence, its possible benefits and risks, how it has been used in studies and commercial products, and how it may interact with medications and daily habits.

Benefits - Risks - Protocol - Conclusion

This section lists high-level overviews of nobiletin written by researchers and longevity-focused publishers.

No relevant content on nobiletin was found from Rhonda Patrick (FoundMyFitness), Peter Attia, Andrew Huberman, Chris Kresser, or Lifespan.io; both web searches and on-site searches of each platform returned no matching articles or episodes.

Grokipedia

  • Nobiletin

    Broad overview of nobiletin’s chemistry, citrus sources, preclinical effects, poor absorption, and animal toxicity data; notes that human trials mostly tested citrus mixtures rather than purified nobiletin.

Examine

No Examine article on nobiletin exists.

ConsumerLab

No ConsumerLab article on nobiletin exists.

Systematic Reviews

The following systematic reviews cover nobiletin, one centred on it and the others as part of broader groups of citrus flavonoids or dietary compounds; none pools human nobiletin trials.

Mechanism of Action

Nobiletin is a polymethoxylated flavone (a citrus flavonoid carrying six methyl groups, which make it fat-soluble). It acts on several targets; which drives its effects is debated.

  • Clock amplification: It binds and activates RORα and RORγ (retinoic acid receptor-related orphan receptors, nuclear receptors that switch on the master clock gene BMAL1), strengthening daily clock-gene cycles in mice (He et al., 2016).
  • Mitochondrial support: Through the same pathway it increased energy production by muscle mitochondria (the cell’s power plants) in high-fat-fed mice (Nohara et al., 2019).
  • Competing explanation: It also inhibits PDE4 (phosphodiesterase 4, an enzyme that breaks down the cell signal cAMP, cyclic adenosine monophosphate), which acutely resets peripheral clocks and releases stress hormones independent of ROR (Ryan et al., 2024); earlier memory research credited signalling that strengthens connections between neurons (review by Nakajima et al., 2014).
  • Dose gap: Most animal effects required 50–200 mg/kg, far above supplement doses.

Pharmacology: Selectivity is low. Water solubility below 1 µg/mL limits absorption. In volunteers given rikkunshito, a Kampo (traditional Japanese herbal) formula containing trace nobiletin, plasma levels peaked within 1 hour and the half-life was about 2.4 hours (Kitagawa et al., 2015); in rats, breakdown products persist 24 hours (Manthey et al., 2011). Being fat-soluble, it distributes into tissues, including brain, in rodents. In human liver preparations, CYP1A2 (an enzyme that clears caffeine and several drugs) and CYP3A4 (the enzyme that clears about half of prescription drugs) break it down by removing methyl groups (Koga et al., 2011).

Historical Context & Evolution

Nobiletin was first isolated in the 1930s from chenpi, the dried mandarin peel used for centuries in traditional Chinese and Japanese Kampo medicine for digestion and cough. It is concentrated in the peel rather than the juice of mandarins, bitter orange, and shiikuwasa (Citrus depressa).

  • Cholesterol era: Canadian researchers showed nobiletin prevented atherosclerosis (plaque build-up in arteries) and insulin resistance (a blunted response to insulin) in mice (Mulvihill et al., 2011). A blend of citrus flavones with palm tocotrienols (vitamin E-family compounds), sold as Sytrinol, was marketed for cholesterol after a positive trial by authors affiliated with the ingredient’s developer and marketer (Roza et al., 2007); a larger independent trial later found no effect beyond placebo (Schuchardt et al., 2015). Neither result settles the question: the products and doses differed.
  • Memory era: Japanese groups reported that nobiletin reversed memory deficits in rodent dementia models (review by Nakajima et al., 2014), and an uncontrolled case series in patients with Alzheimer’s disease followed (Seki et al., 2013).
  • Circadian era: In 2016 an unbiased chemical screen identified nobiletin as a circadian clock enhancer (He et al., 2016), followed by healthy-aging data in mice. This shifted interest toward longevity and prompted circadian supplement products.

What changed over time was the proposed mechanism and the target audience; what did not change is that most evidence remains preclinical.

Expected Benefits

Every human trial below tested a multi-ingredient citrus product; nobiletin alone has never been tested in a human trial.

High 🟩 🟩 🟩

No benefit reaches High: no clinical outcome has been replicated in more than one trial of the same nobiletin preparation.

Medium 🟩 🟩

No benefit reaches Medium: the single-trial results on validated scales all come from multi-ingredient products, which makes them indirect evidence for nobiletin itself.

Low 🟩

Memory and Cognitive Function

In healthy older adults, a 16-week randomized trial of a capsule combining nobiletin, tangeretin (a related citrus flavone), and herbs (Yamada et al., 2021) and a 12-month trial adding nobiletin-rich peel to perilla oil (Hashimoto et al., 2022) improved memory scores. Both had manufacturer co-authors.

Magnitude: WMS-R (Wechsler Memory Scale-Revised, a standard memory test battery) total score rose 9.0 points with the product versus 5.9 with placebo over 16 weeks.

Fewer Night-Time Urinations

In adults over 50 with nocturia (waking at night to urinate), 50 mg daily of nobiletin plus tangeretin after dinner for 6 weeks reduced night-time voids but not the primary endpoint, bladder capacity (Ito et al., 2023). A co-author developed the ingredient.

Magnitude: −0.5 voids per night versus placebo in a crossover trial (each participant received both treatments in turn; 36 completers); night-time bladder capacity +5.7 mL versus placebo, not significant.

Sleep Quality ⚠️ Conflicted

Mouse clock data underlie a proposed sleep benefit, but the only human trial measuring sleep, in older adults with nocturia, found no change in PSQI (Pittsburgh Sleep Quality Index, a validated sleep questionnaire) scores (Ito et al., 2023). Net reading: no sleep benefit has been shown in humans.

Magnitude: Undisturbed sleep rose 0.21 hours with the product versus 0.04 hours with placebo over 6 weeks (difference 0.17 hours, not significant); PSQI scores did not differ.

Lower LDL Cholesterol ⚠️ Conflicted

Two product-linked trials lowered LDL (low-density lipoprotein, “bad” cholesterol) (Roza et al., 2007; Navajas-Porras et al., 2025); a larger independent trial found nothing beyond placebo (Schuchardt et al., 2015). Net reading: a meaningful LDL effect is not established.

Magnitude: LDL −19% to −27% versus placebo in the positive trial; −5.2% versus −4.2% with placebo (no difference) in the 204-person null trial.

Better Blood Sugar Control ⚠️ Conflicted

Product-linked flavone-enriched orange juice lowered HbA1c (3-month blood sugar average) versus placebo juice in dieting obese adults (Navajas-Porras et al., 2025). The product-linked Diabetinol trial (about 515 mg nobiletin daily) showed no significant benefit in type 2 diabetes (Evans et al., 2015). Net reading: no established blood sugar benefit.

Magnitude: Over 24 weeks, Diabetinol versus placebo: HbA1c +0.23% and fasting glucose −14.3 mg/dL, neither statistically significant, with no difference in glucose-tolerance curves; the positive juice trial reported a significant HbA1c decrease.

Preserved Muscle Quality During Stroke Rehabilitation

In a 40-patient pilot trial during stroke rehabilitation, 12 weeks of shiikuwasa fruit extract increased non-fatty muscle area in the unaffected thigh versus placebo (Honaga et al., 2022). Total muscle area did not differ; a food company co-authored.

Magnitude: Non-fatty muscle area on computed tomography in the non-paralyzed thigh rose from 62.0 to 67.7 cm² with the extract versus 61.9 to 62.4 cm² with placebo over 12 weeks; total muscle area did not differ.

Reduced Allergic Eye Symptoms ⭕️ Not Central to Health & Longevity

In cedar-pollen allergy, 2 weeks of mandarin yogurt containing nobiletin reduced eye redness and itching after allergen challenge versus plain yogurt (Hara et al., 2017). This bears on seasonal allergy comfort, not longevity.

Magnitude: Redness score 1.03 versus 1.28 and itching score 1.93 versus 2.82 (mandarin versus control yogurt).

Speculative 🟨

Circadian Clock Enhancement

In obese mice, nobiletin strengthened clock-gene rhythms and raised energy expenditure, requiring a working clock (He et al., 2016). No human study has measured clock-gene rhythms; basis is animal data only.

Healthier Aging and Muscle Energy

Nobiletin improved metabolic fitness in naturally aged mice and boosted muscle energy production in high-fat-fed mice (Nohara et al., 2019). No human aging outcome has been measured.

Longer Lifespan in Worms

Nobiletin extended lifespan, slowed age-related functional decline, and raised stress resistance in the roundworm Caenorhabditis elegans (Yang et al., 2020). No human lifespan data exist; basis is animal data only.

Slowed Alzheimer’s Pathology

Nobiletin reduced amyloid plaque (protein deposits) and brain inflammation in Alzheimer’s model mice (Wirianto et al., 2022). Brain pathology has not been measured in people taking nobiletin; basis is animal data only.

Reduced Atherosclerosis

In cholesterol-prone mice on a Western diet, nobiletin lowered liver fat-particle output, improved insulin sensitivity, and markedly reduced arterial plaque (Mulvihill et al., 2011). Basis is animal data only.

Protection Against Bone Loss

In ovary-removed mice (a model of post-menopausal bone loss), nobiletin reduced bone mineral density loss by 61% and curbed osteoclast (bone-resorbing cell) formation in cells (Murakami et al., 2007). Basis is animal and cell data.

Cancer Chemoprevention

Cell and animal studies show nobiletin inhibits cancer-cell growth, invasion, and blood-vessel formation across several tumor types (review by Chen et al., 2023). No human cancer data exist.

Benefit-Modifying Factors

  • Genetic variation in drug-metabolizing enzymes: Because CYP1A2 and CYP3A4 clear nobiletin, fast CYP1A2 metabolizers (carriers of the rs762551 A allele, a common gene variant, especially smokers) may achieve lower exposure; this is untested.
  • Baseline metabolic status: In mice, benefits were largest under metabolic stress (high-fat diet, genetic obesity) and clock-dependent (He et al., 2016); people with elevated HbA1c or triglycerides are the plausible responders.
  • Baseline cognition: In the memory trial, adults with slightly lower screening scores (MMSE, Mini-Mental State Examination, 24–28) showed an additional figural-memory benefit (Yamada et al., 2021).
  • Sex: No human sex-specific data exist. Female Alzheimer’s model mice showed reduced amyloid pathology and improved metabolic measures with nobiletin (Kim et al., 2021).
  • Kidney function and bladder capacity: In the nocturia trial, responders had smaller night-time bladder capacity and lower serum creatinine than non-responders (Ito et al., 2023).
  • Age: Memory benefits were clearest in adults aged 65–74; those 75 and older showed weaker changes, partly because the memory test is validated only to 75 (Yamada et al., 2021).

Potential Risks & Side Effects

Across the human trials (2 weeks to 12 months, mostly older adults), no serious adverse event was attributed to nobiletin-containing products; in the highest-dose trial (about 515 mg nobiletin daily for 24 weeks), four adverse events on the product, three in one participant, were judged possibly or probably related, without differences in safety labs (Evans et al., 2015). Apart from digestive upset, the risks below are therefore predicted from laboratory data.

High 🟥 🟥 🟥

No risk reaches High: no trial has recorded a specific adverse effect repeatedly attributed to nobiletin, and total human exposure is limited to a few hundred participants.

Medium 🟥 🟥

No risk reaches Medium: the only human adverse events possibly linked to nobiletin come from a single small trial of a multi-ingredient product, which makes them indirect evidence.

Low 🟥

Digestive Upset

In the highest-dose trial, a product supplying about 515 mg nobiletin daily with tangeretin and other citrus compounds, diarrhea and indigestion were judged possibly or probably related to the product (Evans et al., 2015). The lower-dose nocturia trial reported no related events (Ito et al., 2023).

Magnitude: Four possibly or probably related adverse events with the product versus one (nausea) with placebo among 50 randomized participants over 24 weeks; two participants stopped because of diarrhea.

Speculative 🟨

Altered Levels of Prescription Drugs

In cell-culture experiments nobiletin inhibited CYP1A2, and a citrus-flavone mix containing it CYP3A4 (Weiss et al., 2020); in mice it reduced P-gp (P-glycoprotein, a drug-expelling cell pump) (Liu et al., 2022). No human study exists.

Increased Bleeding Tendency

Nobiletin inhibited human platelet clumping and clot formation in cell-culture experiments and prolonged bleeding time in mice (Vaiyapuri et al., 2015). Basis is mechanistic; no human bleeding events are reported.

Reduced Tamoxifen Effectiveness

Tangeretin, which accompanies nobiletin in most citrus products, completely neutralized tamoxifen’s tumor-suppressing effect in mice with human breast cancer (Bracke et al., 1999). Nobiletin itself was not tested.

Skin Sensitivity to UVA Light

Nobiletin protected skin cells against UVB (short-wave ultraviolet) but sensitized them to UVA (long-wave ultraviolet) and simulated sunlight, causing oxidative damage and cell death (Cvammen & Kemp, 2022). Basis is cell culture only.

Acute Stress-Hormone Release

Injected nobiletin sharply raised corticosterone (the rodent equivalent of cortisol) and adrenaline in mice, likely through PDE4 inhibition (Ryan et al., 2024). Whether oral supplement doses do this in humans is unknown.

Risk-Modifying Factors

  • Genetic variation: Slow CYP1A2 metabolizers (rs762551 C allele carriers) may clear nobiletin and co-prescribed CYP1A2-dependent drugs more slowly, raising interaction risk. Untested in humans.
  • Baseline biomarkers: Low platelet count (below 150,000/µL) or elevated INR (international normalized ratio, a clotting-time measure) may amplify nobiletin’s antiplatelet effect.
  • Sex: Women with hormone receptor-positive breast cancer taking tamoxifen face the tangeretin interaction; pregnancy and breastfeeding lack any safety data.
  • Pre-existing conditions: Bleeding disorders, significant liver disease (impaired drug clearance), light-sensitivity disorders, and planned surgery raise risk.
  • Age: Older adults, the most-studied group, tolerated trials well, but taking many medications increases the chance of CYP or P-gp interactions.

Key Interactions & Contraindications

  • Drugs cleared by CYP3A4 with a small margin between effective and toxic levels (tacrolimus, cyclosporine, simvastatin, midazolam): Caution. Possible raised drug levels and toxicity. Mitigation: drug-level monitoring, or avoidance during dose-sensitive therapy.
  • Drugs cleared by CYP1A2 (theophylline, clozapine, tizanidine, caffeine): Caution. Possible increased levels causing jitteriness, sedation, or low blood pressure. Mitigation: symptom and drug-level monitoring; lower caffeine intake.
  • Drugs moved out of cells by P-gp (digoxin, dabigatran): Monitor. Possible increased absorption and effect. Mitigation: digoxin level checks; bleeding surveillance with dabigatran.
  • Anticoagulants and antiplatelets (blood thinners such as warfarin, apixaban, clopidogrel, aspirin): Caution. Additive bleeding risk from platelet inhibition. Mitigation: INR check 1–2 weeks after starting for warfarin users; attention to bruising.
  • Tamoxifen: Avoid tangeretin-containing products. Possible loss of anticancer effect. Mitigation: oncologist review of any tangeretin-containing product.
  • Over-the-counter NSAIDs (non-steroidal anti-inflammatory drugs such as ibuprofen, naproxen): Monitor. Additive platelet inhibition and bleeding risk. Mitigation: limiting regular co-use.
  • Antiplatelet supplements (fish oil, ginkgo, vitamin E, garlic): Monitor. Additive bleeding tendency. Mitigation: not stacking several before procedures.
  • Melatonin: Monitor. Commonly co-formulated; melatonin is cleared by CYP1A2, so levels and next-morning drowsiness may rise. Mitigation: the lowest effective melatonin dose.
  • Other citrus-flavone or grapefruit products (bergamot, tangeretin, grapefruit juice): Caution. Additive CYP inhibition may further raise levels of CYP-dependent drugs, increasing their side effects. Mitigation: no combination with interacting drugs.
  • Additive-effect supplements (berberine, red yeast rice): Monitor. Overlapping glucose- or lipid-lowering effects may cause low blood sugar; red yeast rice also depends on CYP3A4, so muscle side effects may increase. Mitigation: glucose and lipid tracking.
  • UVA phototherapy or tanning beds: Caution. Possible light-induced skin damage. Mitigation: pausing nobiletin around treatment sessions.

Populations who should avoid Nobiletin:

  • Pregnant or breastfeeding women (no safety data)
  • Women with hormone receptor-positive breast cancer taking tamoxifen
  • People with bleeding disorders or platelet count below 100,000/µL
  • People within 2 weeks before scheduled surgery
  • People with moderate-to-severe liver impairment (Child-Pugh Class B or C, a liver-disease severity score)
  • Transplant recipients on tacrolimus or cyclosporine without drug-level monitoring
  • People with known citrus allergy

Risk Mitigation Strategies

  • Drug review before starting: A medication screen for drugs handled by CYP1A2, CYP3A4, or P-gp prevents unrecognized rises in drug levels and resulting toxicity.
  • Clotting check with anticoagulants: For warfarin users, INR measured at baseline and 1–2 weeks after starting catches additive bleeding risk early.
  • Pre-surgical pause: Stopping nobiletin 14 days before surgery or dental extraction limits antiplatelet-related bleeding.
  • Tangeretin-free choice with tamoxifen: Avoiding mixed citrus-flavone products during tamoxifen therapy prevents possible loss of its anticancer effect.
  • Sun protection: Broad-spectrum UVA sunscreen and avoidance of tanning beds reduce the UVA-triggered skin-cell damage seen in laboratory studies.
  • Starting at trial doses: Staying at or below 30 mg nobiletin daily, the range of most human trials, limits digestive upset seen at about 515 mg (Evans et al., 2015) and less-studied high-dose effects such as stress-hormone release.

Therapeutic Protocol

  • Trial-based dosing: Most human trials used 3–30 mg nobiletin daily in mixed products, such as 30 mg plus tangeretin for nocturia (Ito et al., 2023); one diabetes trial used about 515 mg (Evans et al., 2015). No dose-finding study exists.
  • Commercial circadian approach: Life Extension, which popularized and sells nobiletin as a circadian supplement, formulates about 50 mg with melatonin, a dose its scientists extrapolated from animal data (Life Extension magazine article).
  • Preclinical-equivalent approach: Mouse studies used 50–200 mg/kg, which scales to roughly 300–1,100 mg daily for a 70 kg adult; no human safety or efficacy data exist at these doses.
  • Food-based approach: Traditional use of dried mandarin peel (chenpi) or shiikuwasa products supplies nobiletin with other peel compounds, but content varies widely and is rarely labelled.
  • Time of day: In mice, dosing mid-rest phase advanced peripheral clocks while dosing mid-active phase increased rhythm amplitude (Ryan et al., 2024). The nocturia trial dosed after dinner (Ito et al., 2023); human optimal timing is unknown.
  • Half-life: About 2.4 hours, peaking within 1 hour, in volunteers given trace nobiletin in the Kampo formula rikkunshito (Kitagawa et al., 2015); supplement doses are unstudied. In rats, breakdown products persist about 24 hours (Manthey et al., 2011).
  • Single versus split dosing: Most human trials used one daily dose at a fixed time, fitting the circadian rationale; the Diabetinol trial split its dose between morning and evening (Evans et al., 2015). The two schedules have not been compared.
  • Absorption: Taking nobiletin with a fat-containing meal or in lipid-based formulations improves uptake of this poorly water-soluble compound (review by Kesharwani et al., 2020).
  • Genetic polymorphisms: CYP1A2 variants (rs762551) may alter exposure; no genotype-guided dosing exists, and exposure above trial doses is least characterized in slow metabolizers taking interacting drugs.
  • Sex: No sex-specific dosing or response data exist in humans.
  • Age: Trials enrolled mainly adults over 60 at 30 mg or less daily without safety signals; memory benefits were clearest at ages 65–74 (Yamada et al., 2021).
  • Baseline biomarkers: Animal benefits were concentrated under metabolic stress, so response may be larger when fasting glucose, HbA1c, or triglycerides are elevated.
  • Pre-existing conditions: Kidney function and bladder capacity predicted nocturia response (Ito et al., 2023); liver disease may raise exposure.

Discontinuation & Cycling

  • Duration: Nobiletin is used as an open-ended daily supplement; human trials lasted 2 weeks to 12 months, so longer-term use is untested.
  • Withdrawal effects: None are known; no trial reported rebound symptoms after stopping.
  • Tapering: Not required, since no dependence or withdrawal syndrome has been described.
  • Cycling: No data show loss of effect with continuous use or benefit from cycling; the nocturia crossover used a 2-week washout (drug-free gap) without reported problems (Ito et al., 2023).
  • Planned stops: A 14-day pause before surgery is commonly applied because of antiplatelet activity, with resumption once bleeding risk has passed.

Sourcing and Quality

  • Botanical source: Commercial nobiletin is extracted from peels of shiikuwasa (Citrus depressa), mandarin (Citrus reticulata), sweet orange (Citrus sinensis), or bitter orange (Citrus aurantium).
  • Standardization: Quality labels state nobiletin content in milligrams or percent (for example, 20% extracts or purified material near 65% nobiletin with 25% tangeretin) rather than only “citrus flavonoids”.
  • Co-ingredients: Most products also contain tangeretin, relevant to tamoxifen users; bitter-orange extracts can carry synephrine, a stimulant, unless purified.
  • Third-party testing: A certificate of analysis confirming identity by HPLC (high-performance liquid chromatography), potency, and absence of pesticide residues and heavy metals is important, since peels concentrate agricultural chemicals.
  • Formulation: Poor water solubility favors softgels, oil-based, or emulsified forms over dry powder.
  • Available brands: Life Extension (combined with melatonin), Nootropics Depot (standardized extract), and Nobilex (Okinawa Research Center, Japan) are established sources; Sytrinol is a citrus-flavone and tocotrienol ingredient.

Practical Considerations

  • Time to effect: Human trials detected changes after 6 weeks (night-time urination; Ito et al., 2023) to 16 weeks and 12 months (memory; Yamada et al., 2021; Hashimoto et al., 2022); circadian effects in humans have not been measured.
  • Common pitfall - dose mismatch: Supplement doses of 30–50 mg are roughly 6–35 times below the human-equivalent animal doses that produced metabolic and aging benefits.
  • Common pitfall - attributing combination effects: Benefits of melatonin combinations or multi-herb products cannot be credited to nobiletin alone.
  • Common pitfall - unverified content: Products labelled “citrus bioflavonoids” often contain mainly hesperidin with little nobiletin.
  • Regulatory status: Sold as a dietary supplement in the United States and a food product in Japan; not an approved medication anywhere, and not evaluated by the FDA (US Food and Drug Administration) for any use.
  • Cost and access: Widely available online at modest cost; not exceptionally expensive.

Interaction with Foundational Habits

  • Sleep: Potentiating in theory: nobiletin amplifies clock rhythms in mice, and evening dosing was used in the nocturia trial, whose sleep measurement showed no change (Ito et al., 2023). Consistent sleep timing and morning light are the stronger clock signals; dosing at a fixed daily time aligns with them.
  • Nutrition: Potentiating: mouse benefits appeared mainly under high-fat feeding, and absorption improves with dietary fat. Time-restricted eating (confining meals to a daily window of about 8–10 hours) shares the clock-strengthening mechanism. Grapefruit and other citrus-peel products add CYP inhibition; whole citrus peel (zest, marmalade, chenpi tea) supplies small amounts.
  • Exercise: Indirect, potentially potentiating: nobiletin increased muscle mitochondrial energy production in mice (Nohara et al., 2019), overlapping with endurance training adaptations; no human exercise trial exists. There is no evidence of blunted training adaptation, a concern with high-dose antioxidants.
  • Stress management: Uncertain, possibly blunting: injected nobiletin raised stress hormones acutely in mice via PDE4 inhibition (Ryan et al., 2024). Oral human doses have not been tested; tracking sleep onset and anxiety after evening doses gives a practical check.

Monitoring Protocol & Defining Success

Baseline testing before starting establishes reference values for the outcomes nobiletin might affect (glucose, lipids) and for the organs and systems that govern its safety (liver clearance, kidney function, clotting). For people on interacting drugs, baseline drug levels or INR complete the set. A two-week sleep and symptom diary provides a qualitative baseline.

Ongoing monitoring follows this cadence: INR or drug levels at 1–2 weeks after starting when interacting medications are used; metabolic and liver labs at 12 weeks, matching the length of the human trials; then every 6–12 months while use continues. Success is defined as favorable movement in glucose or lipid markers from the individual’s own baseline, stable liver tests, and improved diary measures, since no population target for nobiletin exists.

Biomarker Optimal Functional Range Why Measure It? Context/Notes
Fasting glucose 75–90 mg/dL Glycemic response 8–12 h fast; conventional range 70–99 mg/dL; pair with fasting insulin
HbA1c 4.8–5.3% 3-month glycemic trend Conventional normal below 5.7%; no fasting needed; reflects about 3 months
Fasting insulin 2–6 µIU/mL Insulin sensitivity Conventional range up to about 25 µIU/mL; morning fasting draw
LDL-C Below 100 mg/dL Lipid response (conflicting evidence) LDL-C: low-density lipoprotein cholesterol; conventional target below 130 mg/dL; fasting preferred; pair with ApoB (apolipoprotein B)
Triglycerides Below 100 mg/dL Metabolic response Conventional below 150 mg/dL; requires 10–12 h fast
ALT and AST Below 25 U/L each Liver safety ALT: alanine aminotransferase; AST: aspartate aminotransferase (liver enzymes); conventional upper limit about 40–55 U/L
Creatinine and eGFR eGFR above 90 mL/min/1.73 m² Kidney function baseline eGFR: estimated glomerular filtration rate (kidney filtering capacity); conventional normal above 60; related to nocturia response
Platelet count 150,000–400,000/µL Bleeding risk baseline Part of a complete blood count; same as conventional range
INR (warfarin users only) Individual target set by prescriber, usually 2.0–3.0 Detect interaction Check 1–2 weeks after starting and after dose changes
Levels of CYP-dependent drugs (tacrolimus, cyclosporine, theophylline) Prescriber’s therapeutic range Detect interaction Level drawn just before the next dose, 1–2 weeks after starting; only when these drugs are used

Qualitative markers:

  • Sleep onset time, night-time awakenings, and morning alertness (sleep diary)
  • Number of night-time urinations
  • Daytime energy and consistency of daily rhythm
  • Subjective memory and mental clarity
  • Bruising or prolonged bleeding from minor cuts
  • Skin reactions after sun exposure

Emerging Research

  • Citrus-flavone juice in obesity and diabetes: A completed Spanish randomized trial (NCT06680635) of juice enriched with nobiletin, tangeretin, and sinensetin plus a calorie-restricted diet in 80 adults with obesity, half with type 2 diabetes; primary endpoint insulin resistance. The non-diabetic arm is published (Navajas-Porras et al., 2025).
  • Japanese registry trials: According to their publications, the nocturia (Ito et al., 2023) and memory (Yamada et al., 2021) trials were registered only in Japanese registries, so they have no ClinicalTrials.gov NCT ID; no larger follow-up trials are registered.
  • Clock-targeting cancer therapy: Nobiletin combined with tyrosine kinase inhibitors (cancer drugs blocking growth-signalling enzymes) gave maximal anti-tumor activity in preclinical models of late-stage liver cancer (Fekry et al., 2025); this could strengthen interest in nobiletin as an add-on, pending human data.
  • Heart failure prevention: Nobiletin prevented pressure-overload heart failure (heart failure caused by the heart pumping against persistently raised resistance) in mice by activating SIRT5 (a mitochondrial regulatory enzyme) (Sunagawa et al., 2026); human cardiac data are absent.
  • Evidence that could weaken the case: The independent null cholesterol trial (Schuchardt et al., 2015) and nobiletin’s very poor absorption (review by Kesharwani et al., 2020) suggest supplement doses may not reach active concentrations.
  • Key research gaps: No human absorption-and-clearance study of pure nobiletin, no measurement of human clock-gene rhythms, and no human drug-interaction study exist; each could change the current reading substantially.

Conclusion

Nobiletin is a citrus-peel compound sold as a supplement for the body’s daily clock, metabolism, and brain health. For health-focused adults willing to use targeted supplements, its appeal rests on striking animal results: stronger daily rhythms, protection against weight gain and blood sugar problems, better muscle energy in aging mice, and less brain damage in dementia models.

The human evidence is much thinner. A few small trials in older adults suggest modest gains in memory and less night-time urination, but every trial used a product mixing nobiletin with other citrus compounds or herbs, so the effect of nobiletin itself is unknown. Cholesterol results conflict, and the one human measurement of sleep showed no change. Much of the human research was co-authored by companies that make or sell these products, and the best-known retail formula comes from a seller that also publishes on its benefits.

On the risk side, no consistent side effects have been linked to nobiletin in trials, but laboratory data point to possible effects on blood clotting, on how the liver clears common medicines, on skin sensitivity to sunlight, and, for products containing a related citrus compound, on a breast cancer drug. Doses in supplements are also far below those that worked in animals, which leaves open whether typical use reaches active levels. Overall, nobiletin is a low-risk but largely unproven option whose promise remains mostly in the laboratory.

Top - Benefits - Risks - Protocol